AD1573354

AP20 ROBARTE/PTO 24 MAR 2006

PATENT Attorney Docket No. 059742-5002

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re	Application of: Richard M. Wright et al.)				
U.S.	National Phase of: PCT/US2004/031478)	Group Art Unit: Unassigned			
Inter	national Filing Date: September 27, 2004)	Examiner: Unassigned			
Date	of Entry into U.S. National Stage: March 24, 2006)				
For:	Methods for Modulating Inflammatory)				
	Reactions by Modulating Xanthine)				
	Oxidoreductase Activity)				

INFORMATION DISCLOSURE STATEMENT

UNDER 37 C.F.R. 1.97(b)

Pursuant to 37 C.F.R. 1.56 and 1.97(b), Applicants bring to the attention of the Examiner the documents listed on the attached PTO-1449 forms. This Information Disclosure Statement is being filed, to the best of the undersigned's knowledge, before the mailing date of a first Office Action on the merits for the above-referenced application. Accordingly, Applicants do not believe that a fee is due with the filing of this paper.

Copies of the listed documents are attached. The present application is a U.S. National Phase Application of International Patent Application PCT/US2004/031478, filed September 27, 2004 and published as WO 2005/030138 A2. Documents 1-4 were cited in the International Search Report which issued in International Patent Application PCT/US2004/031478. Applicants respectfully request that the Examiner consider the listed documents and evidence for consideration by making appropriate notations on the attached form.

This submission does not represent that a search has been made or that no better art exists and does not constitute an admission that each or all of the listed documents are material or constitute "prior art." If it should be determined that the listed documents constitute "prior art" under United States law, Applicant reserves the right to present to the office the relevant facts and law regarding the appropriate status of such document.

Attorney Docket No 059742-5002 U.S. National Phase of: PCT/US2004/031478 Page 2765

Applicant further reserves the right to take appropriate action to establish the patentability of the disclosed invention over the listed documents, should one or more of the documents be applied against the claims of the present application.

Except for issue fees payable under 37 C.F.R. §1.18, the Commissioner is hereby authorized by this paper to charge any additional fees during the entire pendency of this application including fees due under 37 C.F.R. §§1.16 and 1.17 which may be required, including any required extension of time fees, or to credit any overpayment to Deposit Account No. 50-0310. This paragraph is intended to be a CONSTRUCTIVE PETITION FOR EXTENSION OF TIME in accordance with 37 C.F.R. §1.136(a)(3).

Dated: March 24, 2006 Morgan, Lewis & Bockius LLP Customer No. 09629 1111 Pennsylvania Avenue Washington, D.C. 20004 202-739-3000 Respectfully submitted,
Morgan, Lewis & Bockius LLP

(Gregory T. Lowen)

Lucy Jewy Reg. No. 46,882

Sally P. Teng, Ph.D.

Registration No. 45,397

APANTE GIRBERT

INFORMATION DISCLOSURE CITATION (Use several sheets if necessary) PTO Form 1449			Attorney Docket No. 059742-5002			U.S. National Phase of						
			Applicants: Richard M. Wri									
			Filing Date: March 24, 2006			Group Art Unit: Unassigned						
U.S. PATENT DOCUMENTS												
Initial		Document No.	Date		Name	Class	Sub-Class	Filing Date				
	_											
				L		l	ll					
FOREIGN PATENT DOCUMENTS												
		Document No.	Date		Country	Class	Sub-Class	Translation				
							-					
		-										
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)												
	1.	Meneshian et al. (2002)	'The physiology of	endothelial	xanthine oxidase:			to reperfusion injury to				
	_	inflammatory signal transduction" Microcirculation 9(3):161-175										
	2.	Okamoto et al. (1995) "Mechanism of inhibition of xanthine oxidase with a new tight binding inhibitor" J Biol Chem. 270(14):7816-7821										
	3.	d]pyrimidines" J Biol C	hem. 245(11):2837-	chanism of inactivation of xanthine oxidase by allopurinol and other pyrazolo[3,4- 5(11):2837-2844								
	4.	Sanders et al. (1997) "NADH oxidase activity of human xanthine oxidoreductase—generation of superoxide anion" Eur J Biochem. 245(3):541-548										
						-						
	-											
			_									
	_											
	_											
		-										
	_											
Zvamine-	1000	L an Basquill/ (06/21/20	10)	onsidered	00/04/0046							
		, ,	,		06/21/2010)				
Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in												